Background: Visual snow syndrome is a phenomenon for which no effective treatment is known. It is highly comorbid with migraine, therefore we performed a retrospective chart review of patients with visual snow syndrome treated with a monoclonal antibody against calcitonin gene related peptide or its receptor.
Findings: We enrolled 15 patients with visual snow syndrome who received at least once a monoclonal antibody against calcitonin gene related peptide or its receptor. None of the patients reported relief of visual snow syndrome whereas those patients with comorbid migraine reported a very good efficacy of the antibody against the migraine headache but not against the migraine aura.
Conclusion: The data suggest that visual snow syndrome is not mediated by calcitonin gene related peptide in a relevant way and that the calcitonin gene related peptide receptor is not involved in the network underlying the visual snow syndrome.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/03331024221099220 | DOI Listing |
Neurology
January 2025
From the Department of Neuro-Ophthalmology (S.H.W.), Moorfields Eye Hospital NHS Foundation Trust; Departments of Ophthalmology and Neurology (S.H.W.), Guy's and St Thomas' NHS Foundation Trust; Department of Ophthalmology (S.H.W.), Faculty of Life Sciences & Medicine, King's College London; Department of Clinical and Movement Neuroscience (S.H.W.), UCL Queen Square Institute of Neurology, University College London, United Kingdom; Department of Ophthalmology and Visual Sciences (R.A., W.T.C., T.D., J.R.E., C.A.A., L.B.D.L.), Kellogg Eye Center, University of Michigan, Ann Arbor; Departments of Ophthalmology, Neurology, and Neurosurgery (E.R.E., S.K.), Mayo Clinic, FL; Survey Research Center (J.R.E.), Institute for Social Research, University of Michigan, Ann Arbor; and Division of Neurology (C.B.-T.), Department of Medicine, University Health Network and University of Toronto, Ontario, Canada.
Background And Objectives: Ocular myasthenia gravis (OMG) causes disabling ocular symptoms of ptosis and diplopia, but a validated disease-specific patient-reported outcome measure (PROM) has not been reported. We sought to validate a novel PROM for OMG, OMG Rating Scale Questionnaire (OMGRate-q), as a measure of visual functioning to support patient-centered care.
Methods: This was a prospective study of patients aged 18 years and older with OMG receiving care at 3 medical centers (January 2022-October 2023).
Nervenarzt
December 2024
Klinik für Neurologie, Oberbayerisches Kopfschmerzzentrum, Klinikum Großhadern, Ludwig-Maximilians-Universität, München, Deutschland.
Ann Clin Transl Neurol
December 2024
Melbourne School of Psychological Sciences, University of Melbourne, Parkville, Australia.
Objective: This study aimed to investigate the nature of subclinical Visual Snow Syndrome (VSS). We sought to develop a means of recruiting naïve participants with subclinical VSS symptoms to participate in research; and to understand whether subclinical VSS symptoms are stable across time. VSS is a recently characterised neurological condition, whose primary symptom is visual snow (dynamic noise in the visual field).
View Article and Find Full Text PDFInvest Ophthalmol Vis Sci
October 2024
Department of Optometry and Vision Sciences, University of Melbourne, Parkville, Australia.
Purpose: Palinopsia (persistent afterimages and/or trailing) is a common but poorly understood symptom of the neurological condition visual snow syndrome. This study aimed to collect a phenotypical description of palinopsia in visual snow syndrome and probe for abnormalities in temporal visual processing, hypothesizing that palinopsia could arise from increased visibility of normal afterimage signals or prolonged visible persistence.
Methods: Thirty controls and 31 participants with visual snow syndrome (18 with migraine) took part.
Brain Commun
September 2024
Laboratory of Psychophysics, Brain Mind Institute, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
Patients with visual snow syndrome (VSS) experience uncountable flickering tiny dots in the entire visual field. Symptoms often persist over the years. Very little is known about altered perception in VSS.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!